This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 2013, for instance, I published an essay titled “ A Declaration of Psychedelic Studies ,” which began with these words: “The scientific research community is in the midst of a ‘psychedelic renaissance,’ but sanctioned platforms for mainstream discussion are heavily weighted in the direction of objective scientific research.
(he/him or they/them) has been personally utilizing psychedelics and other substances in celebratory and spiritual contexts for over fifteen years, and has been actively participating in the drug policy reform movement since 2013.
ANVISA’s RDC 665/2022 (link in Portuguese) replaces previous regulations, including RDC 16/2013 and IN 08/2013, and went into effect on 02 May 2022. ANVISA has issued a new resolution that updates Brazilian Good Manufacturing Practices (BGMP) for medical devices and in vitro diagnostic (IVD) products.
439, 448 (2013). [15] Sugarman, 566 F.2d 2d 817, 825 (2d Cir. 13] San Antonio Indep. Rodriguez, 411 U.S. 1, 35 (1973). [14] 14] Erin C. Fuse Brown, Developing a Durable Right to Health Care , 14 Minn. & Tech. 15] Emily Parker, Constitutional Obligations for Public Education , Educ.
Plaintiff knew about it, too, since he signed an informedconsent document mentioning it. The G/N MDL was created in 2013 and mostly settled in 2016. In Cates the plaintiff encountered an unusual – so unusual as to be called “paradoxical” − but known, adverse reaction. The device labeling specifically mentioned it. 13) McGee v.
Bexis’ amicus efforts this year in Mallory obviously came to naught, and we’ve had our own cases on this list before (see, e.g. , 2013-2 and 2021-10 ). If you’ve been burned by any of these judicial debacles, we sympathize. A lawyer who never loses doesn’t litigate hard cases. The penalty did not hold up, but the duty did.
Another motion reflected Bexis original position (but wasn’t Bexis’ motion), that the Institute should prepare black letter, comments and reporters’ notes for both sides of this issue, similarly to the manner in which the same draft handled the question of patient-oriented versus physician-oriented standards for informedconsent.
2013) (Painter); McClellan v. 2019) (Augustine); In re Mirena IUD Levonorgestrel-Related Products Liability Litigation (No. II) , 341 F. 3d 213, 222-23, 229-32 (S.D.N.Y. 2018) (Etminan); Gerke v. Travelers Casualty Insurance Co. , 316, 328-29 (D. I-Flow Corp. , 2d 1092, 1119-25 (D. 2010) (Matsen); Nelson v. Tennessee Gas Pipeline Co.
2013 WL 4516160, at *3 (N.M. 2013 WL 85291, at *8 (D.N.J. 7, 2013) (no causation given prescriber’s “testimony that he would prescribe [the drug] to Plaintiff again even with the benefit of the additional. . . 2013 WL 1758647, at *5 (D.N.J. SmithKline Beecham Corp. April 26, 2018); Cooper v. Bristol-Myers Squibb Co.
2013 WL 2457950, at *8 (N.D. June 6, 2013) (no causation where the prescriber “believed that any risk associated with the drug was heavily outweighed by the benefits of treating what he suspected was. . . 2014); In re Trasylol Products Liability Litigation , 2013 WL 1080552 at *12 (S.D. 2013 WL 1758647, at *5 (D.N.J.
That’s why we’re pleased with the ruling in InformedConsent Action v. A CDC study published in 2013 added to the research showing that vaccines do not cause ASD. Well, it’s not just the tort plaintiffs who want to litigate scientific opponents into submission, and it’s not just our clients being targets of such efforts.
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content